Risk Assessment of COVID-19 on Patients with Chronic Kidney Diseases in Libya
DOI:
https://doi.org/10.58987/nk5vpv84Keywords:
COVID-19, Pandemic, Chronic Kidney Disease (CKD), Mortality, Diabetes, HypertensionAbstract
The Sars covid 19 virus is an extremely contagious disease that originated in Wuhan, China, in late 2019. Widespread panic over the news of the infectious disease quickly followed, and despite most countries inflicting lockdown restrictions, the virus spread nonetheless, reaching over 230 countries and territories as of October 2022. This study is to provide insight into managing CKD patients' with COVID-19, and to declare that the diseases’ outcome was affected by individual factors on Libyan CKD patients. Data of 635 CKD patients were collected from Al-Shatt Road Kidney Diseases Center in Tripoli, from January to September 2020. Statistical analysis was conducted to assess the risk of this pandemic on kidney patients and to evaluate the impact of several related factors: gender, age, and CKD associated diseases. The rate of mortality among CKD patients COVID infected was determined as well. The results of this study showed that 18.5% of CKD patients tested positive for COVID-19, while 81.5% tested negative. The highest number among CKD with COVID-19 were males 58.8% vs female 41.2%. Patients with hypertension and diabetes age >45 were more vulnerable to COVID-19 than other CKD patients. In additions, 74% of CKD patients developed diabetes after COVID 19 infection. The fatality rate of CKD- COVID 19 positive was significantly higher than CKD- COVID 19 negative (29.8 % vs 2.3%) and male’s mortality rate was significantly higher than females, p-value <0.05 through the nine months of observation. Hemodialysis is a significant variable for Corona’s chance of infection. These results may be beneficial for CKD patients who may benefit from appropriate, specialized and efficient medical treatment. Further research considers studding the long-term damage of COVID-19 on public health.
References
Downloads
Published
Issue
Section
License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
1. Retention of Rights: Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0).
2. User Rights: This license allows others to remix, tweak, and build upon the work non-commercially, and although their new works must also acknowledge the original author and be non-commercial, they do not have to license their derivative works on the same terms.
3. Restrictions: The material cannot be used for commercial purposes without prior written permission from the author or the journal.
4. Additional Agreements: Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository), with an acknowledgement of its initial publication in this journal.